DOI | 10.1038/s41586-020-2168-1
|
| Multispecific drugs herald a new era of biopharmaceutical innovation |
| Gallego, Laura D.1; Schneider, Maren1; Mittal, Chitvan2; Romanauska, Anete1; Carrillo, Ricardo M. Gudino1; Schubert, Tobias1; Pugh, B. Franklin2; Koehler, Alwin1
|
| 2020-03-11
|
发表期刊 | NATURE
![](/C666/image/waiting.gif) |
ISSN | 0028-0836
|
EISSN | 1476-4687
|
出版年 | 2020
|
卷号 | 580期号:7803页码:329-338 |
文章类型 | Review
|
语种 | 英语
|
国家 | USA |
英文关键词 | The modern biopharmaceutical industry traces its roots to the dawn of the twentieth century, coincident with marketing of aspirin-a signature event in the history of modern drug development. Although the archetypal discovery process did not change markedly in the first seven decades of the industry, the past fifty years have seen two successive waves of transformative innovation in the development of drug molecules: the rise of '
rational drug discovery'
methodology in the 1970s, followed by the invention of recombinant protein-based therapeutic agents in the 1980s. An incipient fourth wave is the advent of multispecific drugs. The successful development of prospectively designed multispecific drugs has the potential to reconfigure our ideas of how target-based therapeutic molecules can work, and what it is possible to achieve with them. Here I review the two major classes of multispecific drugs: those that enrich a therapeutic agent at a particular site of action and those that link a therapeutic target to a biological effector. The latter class-being freed from the constraint of having to directly modulate the target upon binding-may enable access to components of the proteome that currently cannot be targeted by drugs.
|
领域 | 地球科学
; 气候变化
; 资源环境
|
收录类别 | SCI-E
|
WOS记录号 | WOS:000530151300022
|
WOS关键词 | BLOOD-BRAIN-BARRIER
; BISPECIFIC MONOCLONAL-ANTIBODY
; IN-VIVO
; BREFELDIN-A
; T-CELLS
; SELECTIVE DEGRADATION
; STRUCTURAL BASIS
; TARGET
; LENALIDOMIDE
; THALIDOMIDE
|
WOS类目 | Multidisciplinary Sciences
|
WOS研究方向 | Science & Technology - Other Topics
|
引用统计 |
|
文献类型 | 期刊论文
|
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/281371
|
专题 | 地球科学 资源环境科学 气候变化
|
作者单位 | 1.Med Univ Vienna, Max Perutz Labs, VBC, Vienna, Austria; 2.Penn State Univ, Ctr Eukaryot Gene Regulat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA
|
推荐引用方式 GB/T 7714 |
Gallego, Laura D.,Schneider, Maren,Mittal, Chitvan,et al. Multispecific drugs herald a new era of biopharmaceutical innovation[J].
NATURE,2020,580(7803):329-338.
|
APA |
Gallego, Laura D..,Schneider, Maren.,Mittal, Chitvan.,Romanauska, Anete.,Carrillo, Ricardo M. Gudino.,...&Koehler, Alwin.(2020).Multispecific drugs herald a new era of biopharmaceutical innovation.NATURE,580(7803),329-338.
|
MLA |
Gallego, Laura D.,et al."Multispecific drugs herald a new era of biopharmaceutical innovation".NATURE 580.7803(2020):329-338.
|
修改评论